BioSphere Medical to Broadcast Second-Quarter Conference Call Live Over the Internet.Business/Technology Editors & Health/Medical Writers ROCKLAND, Mass.--(BW HealthWire)--July 10, 2001 BioSphere Medical (Nasdaq: BSMD), a medical device company that is pioneering the use of bioengineered microspheres in embolotherapy, plans to announce its second-quarter 2001 financial results before the market opens on Thursday, July 19, 2001. The Company will conduct its quarterly conference call at 10:00 a.m. (ET) on Thursday, July 19. The conference call will be broadcast live over the Internet. Investors interested in listening to the call should log onto the company's Web site at www.biospheremed.com at least 15 minutes prior to the broadcast. Investors can also access an archived version of the call on the company's Web site. About BioSphere Medical, Inc. BioSphere Medical, Inc., based in Rockland, Massachusetts, is a medical device company with a microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. platform technology. The Company's primary focus is embolotherapy, the treatment of hypervascularized tumors and arteriovenous malformations Arteriovenous Malformations Definition Arteriovenous malformations are blood vessel defects that occur before birth when the fetus is growing in the uterus (prenatal development). The blood vessels appear as a tangled mass of arteries and veins. by occluding their blood supply. The Company is pioneering the use of patented and proprietary bioengineered microspheres as a new class of embolics. BioSphere Medical's lead product, Embosphere(R)Microspheres, was cleared by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in April 2000 for marketing for hypervascularized tumors and arteriovenous malformations. The Company is currently conducting clinical trials of Embosphere Microspheres for uterine fibroid embolization Uterine Fibroid Embolization Definition Uterine fibroids are growths in the muscular tissue of the womb (uterus). Uterine fibroid embolization is non-surgical removal of the growths through the use of a tubular device called a catheter. in the United States under an Investigational Device Exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) granted by the FDA. BioSphere Medical has received CE Mark approval in the European Community and approvals in Canada and Australia which allow the company to market Embosphere Microspheres for use in general embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun) 1. the process or condition of becoming an embolus. 2. therapeutic introduction of a substance into a vessel in order to occlude it. procedures, including uterine fibroid embolization. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion